Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

On the Couch

On the Couch artwork

On the Couch with Dr Nina Webster (DXB): Biotech Breakthroughs and DXB's Year Ahead

Feb 21, 202522 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Welcome to another episode of On the Couch, the podcast series where we chat with brokers, CEOs, and fund managers to give you valuable insights into the investing world. In this episode, Henry Jennings is joined by Dr Nina Webster, CEO and Managing Director of Dimerix (ASX: DXB), a clinical-stage biopharmaceutical company working on treatments for inflammatory diseases. With a market cap of $270 million, Dimerix is advancing its proprietary Phase 3 candidate DMX-200 to treat Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease, and is also developing DMX-700 for respiratory disease. Nina has over 30 years of experience in the pharmaceutical industry, with leadership roles across research, development, and commercialisation. She was formerly Commercial Director at Acrux (ASX: ACR), an Australian pharmaceutical company that successfully developed and commercialised multiple products globally. She is also Non-Executive Chairperson for SYNthesis BioVentures and a Non-Executive Director at Linear Clinical Research Limited. Dr Webster holds a Ph.D in Pharmaceutics from Cardiff University, a Bachelor’s degree in Pharmacology, a Master’s in Intellectual Property Law from Melbourne University, and an Executive MBA from RMIT. Talking Points: Dimerix is focused on developing and commercialising new treatments for inflammatory diseases with poor outcomes. The leading drug candidate is a treatment for a rare kidney disease known as FSGS - what’s the nature of this disease and its current treatment? What’s changed, and how did DXB come about? DMX-200 is now in a global Phase 3 clinical trial - an update on the trial and when results are expected. The upside from here following DXB’s strong run. Are all the eggs in one basket if this trial is not successful? What is Plan B? Three successful commercial deals - how they came together. CEOs shouldn’t speculate on future licensing deals, but the US market is always the big one. What interest has there been from US pharma companies? How does what’s happening in the US impact Dimerix? Elon Musk has been vocal about the FDA, and with Kennedy in charge, is there extra risk of regulatory slowdowns? NEU as a playbook - Dr Webster previously worked with NEU’s CEO at Acrux. Is Dimerix a bona fide Neuren replica? Cash reserves and burn rate - what’s the current financial position? Who are Dimerix’s biggest shareholders? If the FSGS trial goes well, what happens next? Licensing? What will be the major Dimerix milestones for 2025? A deep dive into Dimerix, the biotech sector, and what’s ahead for the company. Listen now to hear the full conversation. Disclaimer: This is general advice only. Please consult your financial adviser before making any investment decisions. If you’re looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services. Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. On the Couch with Dr Samantha South (ASX: PAB): Repurposing an Established Drug for Delirium

    Nov 20, 202629 minAudio

    In this episode of On the Couch, Henry Jennings speaks with Dr Samantha South, CEO of Patrys (ASX: PAB). Samantha explains delirium, an acute brain dysfunction that can cause confusion, agitation and hallucinations, and...

    Credit the people on this episode

  2. On the Couch with Ryan MacNeill (ASX: EQR): Why Tungsten Is in Focus at IMARC 2026

    Nov 20, 202616 minAudio

    In this episode of On the Couch, Henry Jennings sits down with Ryan MacNeill, General Manager of Sales and Marketing at EQ Resources (ASX: EQR), at the International Mining and Resources Conference (IMARC) 2026....

    Credit the people on this episode

  3. On the Couch with Richard Morrow (ASX: LRT): Copper, Gold and Critical Minerals at IMARC 2026

    Nov 13, 202615 minAudio

    In this episode of On the Couch, Henry Jennings sits down with Richard Morrow, Director of Lowell Resources Funds Management, at the International Mining and Resources Conference (IMARC) 2026. Recorded live in the OnAir...

    Credit the people on this episode

  4. On the Couch with Jim McKerlie (ASX: IPT): From Explorer to Advanced Materials at IMARC 2026

    Nov 13, 202616 minAudio

    In this episode of On the Couch, Henry Jennings sits down with Jim McKerlie, Chairman of Impact Minerals (ASX: IPT), at the International Mining and Resources Conference (IMARC) 2026. Recorded live in the OnAir podcast...

    Credit the people on this episode

  5. On the Couch with David Newling (ASX: AR1): Why Queensland Copper Is Consolidating at IMARC 2026

    Nov 11, 202611 minAudio

    In this episode of On the Couch, Henry Jennings speaks with David Newling, Chairman of Austral Resources (ASX: AR1), at the International Mining and Resources Conference (IMARC) 2026. Recorded live in the OnAir podcast...

    Credit the people on this episode